Cargando…

LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review

OBJECTIVES: The aim of this study was to assess the current evidence for long-acting β(2)-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) in the treatment of COPD. MATERIALS AND METHODS: A systematic literature search of randomized controlled trials published i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rogliani, Paola, Calzetta, Luigino, Braido, Fulvio, Cazzola, Mario, Clini, Enrico, Pelaia, Girolamo, Rossi, Andrea, Scichilone, Nicola, Di Marco, Fabiano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174911/ https://www.ncbi.nlm.nih.gov/pubmed/30323582 http://dx.doi.org/10.2147/COPD.S170606

Ejemplares similares

LABA/LAMA combination in COPD: a meta-analysis on the duration of treatment
por: Calzetta, Luigino, et al.
Publicado: (2017)

Potential Drawbacks of ICS/LABA/LAMA Triple Fixed-Dose Combination Therapy in the Treatment of Asthma: A Quantitative Synthesis of Safety Profile
por: Rogliani, Paola, et al.
Publicado: (2022)

Single Inhaler LABA/LAMA for COPD
por: Malerba, Mario, et al.
Publicado: (2019)

Pharmacology of novel treatments for COPD: are fixed dose combination LABA/LAMA synergistic?
por: Spina, Domenico
Publicado: (2015)

Inhaler Devices for Delivery of LABA/LAMA Fixed-Dose Combinations in Patients with COPD
por: D’Urzo, Anthony, et al.
Publicado: (2019)

Comparing the Efficacy and Safety Profile of Triple Fixed-Dose Combinations in COPD: A Meta-Analysis and IBiS Score
por: Rogliani, Paola, et al.
Publicado: (2022)

Quantitative analysis of efficacy and safety of LABA/LAMA fixed-dose combinations in the treatment of stable COPD
por: Gong, Yiwen, et al.
Publicado: (2022)

LABA/LAMA fixed-dose combinations versus LAMA monotherapy in the prevention of COPD exacerbations: a systematic review and meta-analysis
por: Chen, Ching-Yi, et al.
Publicado: (2020)

Extrafine triple therapy delays COPD clinically important deterioration vs ICS/LABA, LAMA, or LABA/LAMA
por: Singh, Dave, et al.
Publicado: (2019)

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis
por: Rodrigo, Gustavo J, et al.
Publicado: (2017)

LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes
por: Hizawa, Nobuyuki
Publicado: (2015)

Differences in Pulmonary Function Improvement after Once-Daily LABA/LAMA Fixed-Dose Combinations in Patients with COPD
por: Huang, Wei-Chun, et al.
Publicado: (2022)

The clinical use of regenerative therapy in COPD
por: Lipsi, Roberto, et al.
Publicado: (2014)

EVELUT®: A Real-World, Observational Study Assessing Dyspnoea and Symptom Burden in COPD Patients Switched from LABA/ICS to LAMA/LABA or LAMA/LABA/ICS
por: Buhl, Roland, et al.
Publicado: (2023)

Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis
por: Aziz, Mohamed Ismail Abdul, et al.
Publicado: (2018)

Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies
por: Palli, Swetha R, et al.
Publicado: (2021)

Dual therapy strategies for COPD: the scientific rationale for LAMA + LABA
por: Cohen, Joshua S, et al.
Publicado: (2016)

Clinical Interpretation of Efficacy Outcomes in Pharmacological Studies on Triple Fixed-Dose Combination Therapy for Uncontrolled Asthma: Assessment of IRIDIUM and ARGON Studies
por: Rogliani, Paola, et al.
Publicado: (2022)

UK-specific cost-effectiveness of tiotropium + olodaterol fixed-dose combination versus other LAMA + LABA combinations in patients with COPD
por: Tebboth, Abigail, et al.
Publicado: (2016)

Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal
por: Vanfleteren, Lowie, et al.
Publicado: (2018)

Triple therapy (ICS/LABA/LAMA) in COPD: thinking out of the box
por: Vanfleteren, Lowie E.G.W., et al.
Publicado: (2019)

Day and Night Control of COPD and Role of Pharmacotherapy: A Review
por: Braghiroli, Alberto, et al.
Publicado: (2020)

Triple Therapy Versus Dual Bronchodilation and Inhaled Corticosteroids/Long-Acting β-Agonists in COPD: Accumulating Evidence from Network Meta-Analyses
por: Cazzola, Mario, et al.
Publicado: (2019)

Sex differences in adult asthma and COPD therapy: a systematic review
por: Rogliani, Paola, et al.
Publicado: (2022)

The impact of dual bronchodilation on cardiovascular serious adverse events and mortality in COPD: a quantitative synthesis
por: Rogliani, Paola, et al.
Publicado: (2017)

Population-based study of LAMA monotherapy effectiveness compared with LABA/LAMA as initial treatment for COPD in primary care
por: Barrecheguren, Miriam, et al.
Publicado: (2018)

Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation
por: Cazzola, Mario, et al.
Publicado: (2017)

Why small particle fixed dose triple therapy? An excursus from COPD pathology to pharmacological treatment evolution
por: Braido, Fulvio, et al.
Publicado: (2022)

When is LABA/LAMA Better than LAMA in GOLD Group B or D Patients for Reducing Acute Exacerbations of COPD?
por: Shin, Hong-Joon, et al.
Publicado: (2023)

Treatment with LABA versus LAMA for stable COPD: a systematic review and meta-analysis
por: Koarai, Akira, et al.
Publicado: (2020)

LABA/LAMA as First-Line Therapy for COPD: A Summary of the Evidence and Guideline Recommendations
por: Miravitlles, Marc, et al.
Publicado: (2022)

Age does not affect the efficacy of anti-IL-5/IL-5R in severe asthmatics
por: Principe, Stefania, et al.
Publicado: (2019)

Clinically Important Deterioration (CID) and Ageing in COPD: A Systematic Review and Meta-Regression Analysis According to PRISMA Statement
por: Manzetti, Gian Marco, et al.
Publicado: (2023)

Stem Cell-Based Regenerative Therapy and Derived Products in COPD: A Systematic Review and Meta-Analysis
por: Calzetta, Luigino, et al.
Publicado: (2022)

Effects of LAMA/LABA Alone and in Combination on Cardiac Safety
por: Andreas, Stefan
Publicado: (2020)

Patient Characteristics and Healthcare Resource Utilization Among Patients with COPD New to LAMA/LABA Fixed-Dose Combination Treatment in US-Based Real-World Practice
por: Ding, Bo, et al.
Publicado: (2020)

Gender-related Responsiveness to the Pharmacological Treatment of COPD: A First Step Towards the Personalized Medicine
por: Calzetta, Luigino, et al.
Publicado: (2017)

SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines
por: Rogliani, Paola, et al.
Publicado: (2021)

Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?
por: Tariq, Syed Mohammad, et al.
Publicado: (2017)

Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis
por: Cazzola, Mario, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_i3jchd917c6sguke20f71q6qea